secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acumen Pharmaceuticals, Inc. (ABOS)
CIK:        0001576885
Form:       8-K
Filed at:   2026-05-12T11:07:44+00:00
Accession:  0001628280-26-033868
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acumen posts Q1 net loss $20.7M; Phase 2 AD topline results expected late 2026
------------------------------------------------------------------------------

- Cash and marketable securities totaled $128.4M as of Mar 31, 2026; funded into early 2027.
- Net loss $20.7M for Q1 2026 vs $28.8M in Q1 2025; R&D expense fell to $16.5M from $25.3M.
- Topline results from Phase 2 ALTITUDE-AD study (sabirnetug, early Alzheimer's) due late 2026.
- Option to license two candidates from JCR EBD collaboration expected in Q2 2026.
- Targeting IND filing for EBD lead candidate in mid-2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576885/000162828026033868/0001628280-26-033868-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576885/000162828026033868/abos-20260512.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-033868

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer